Sam D. Sherman
Associate
Sam Sherman is an associate in the Axinn's Antitrust group. His practice focuses on antitrust transactions, litigation, and government investigations. He has represented both U.S. and multinational clients across a variety of sectors, including life sciences, technology, and cannabis.
Sam D. Sherman
Associate
Sam Sherman is an associate in the Axinn's Antitrust group. His practice focuses on antitrust transactions, litigation, and government investigations. He has represented both U.S. and multinational clients across a variety of sectors, including life sciences, technology, and cannabis.
Sam earned his JD at Stanford Law School, where he was awarded the John Hart Ely Prize for Outstanding Performance in Lawyering for Innovation in Artificial Intelligence and also earned two Gerald Gunther Prizes for Outstanding Performance in Communications Law. Sam was a summer associate with Axinn in 2019.
Prior to law school, he was a Research Fellow at Stanford University, where he used cutting-edge social scientific methods to study difficult questions of law and public policy and co-authored two articles about improving government service delivery based on empirical evidence. Sam holds a BA in Mathematics and Economics from Wake Forest University, where he was a Nancy Susan Reynolds Scholar and recipient of the David and Lelia Farr Prize for Excellence in Economics (awarded to one graduating economics major for outstanding achievement).
Education
- JD – Stanford Law School (2020)
- BA, summa cum laude – Wake Forest University (2015)
Admissions
- District of Columbia
- Maryland
Quotes
The lawyers have a deep knowledge of antitrust laws.
Chambers USA
News & Insights
News & Insights
The FTC’s New Unfair Methods of Competition Policy Statement: To What Extent Will The Approach Survive in Court?
Publications
Antitrust
Antitrust Litigation is Coming to Cannabis
Publications
Antitrust
Axinn Matter Named 2022 GCR Behavioural Matter of the Year – Americas
News
Antitrust
Big Trouble for Biglari Under the HSR Act – and Why Cannabis Operators Should Take Note
Publications
Antitrust
Axinn Advised Columbia Care in its $240M Acquisition of Green Leaf Medical
News
Antitrust
Cost and Opportunity in Suspending Early Merger Clearances
Publications
Antitrust